Last updated: July 31, 2026
Brethine is the former U.S. brand name for terbutaline sulfate, a short-acting beta-2 adrenergic agonist used primarily as a bronchodilator. The product has limited current commercial relevance as a branded medicine. U.S. demand is supplied mainly through generic terbutaline tablets and injectable products, while inhaled beta-2 agonists such as albuterol dominate outpatient asthma treatment. No major late-stage clinical development program is associated with Brethine or terbutaline for a new branded indication.
What is Brethine and how is terbutaline used?
Brethine contains terbutaline sulfate, a selective beta-2 adrenergic agonist. Terbutaline relaxes bronchial smooth muscle and can reduce bronchospasm associated with asthma, chronic bronchitis, and emphysema.
| Attribute |
Brethine and terbutaline |
| Active ingredient |
Terbutaline sulfate |
| Drug class |
Short-acting beta-2 adrenergic agonist |
| Historical brand |
Brethine |
| U.S. dosage forms |
Oral tablets and subcutaneous injection |
| Common tablet strengths |
2.5 mg and 5 mg |
| Principal use |
Bronchospasm associated with reversible obstructive airway disease |
| Regulatory status |
Generic prescription drug; legacy brand positioning |
| Main competitors |
Albuterol, levalbuterol, inhaled corticosteroid combinations, nebulized bronchodilators |
| Commercial status |
Mature, low-growth generic market |
Terbutaline is less commonly selected than albuterol because albuterol is available in widely used metered-dose inhalers, dry-powder inhalers, nebulizer solutions, and combination products. Terbutaline's oral and injectable routes remain relevant in selected clinical settings but are not the dominant treatment approach for routine asthma management.
What is the FDA status of Brethine and terbutaline?
Brethine is not a major current branded product in the U.S. market. Terbutaline sulfate remains available through generic prescription products, including oral tablets and injectable formulations.
The FDA has taken a restrictive position on terbutaline use for prevention or treatment of preterm labor. In 2011, the agency warned against prolonged use of injectable terbutaline and against oral terbutaline for prevention or treatment of preterm labor because of the risk of serious maternal cardiovascular events and death. The FDA stated that terbutaline should not be used for prolonged treatment of preterm labor beyond 48 to 72 hours and should not be used in an outpatient or home setting for that purpose.[1]
FDA regulatory milestones
| Date |
Regulatory development |
| Historical period |
Terbutaline approved and marketed as a bronchodilator under several brand and generic labels |
| 1990s–2000s |
Generic competition expanded; albuterol became the dominant short-acting beta-2 agonist |
| February 2011 |
FDA issued a safety communication restricting obstetric use for preterm labor |
| 2011 onward |
Terbutaline remained available for approved bronchodilator indications |
| Current market |
Generic terbutaline remains available, with no material new branded Brethine development program |
The applicable FDA labeling distinguishes approved bronchodilator use from obstetric use. Use for preterm labor is not an approved long-term indication in the United States.
Are there active clinical trials for Brethine or terbutaline?
There is no significant active clinical-trial program for Brethine as a new branded product. Clinical research involving terbutaline has generally been investigator-led or focused on niche clinical questions rather than commercial redevelopment.
ClinicalTrials.gov records historically include studies involving terbutaline in areas such as:
- Bronchospasm and obstructive airway disease
- Neonatal and pediatric respiratory conditions
- Tocolysis and preterm labor
- Drug safety and comparative obstetric treatment
- Pharmacology and route-of-administration studies
The existence of a terbutaline trial does not indicate an active Brethine product-development program. Current commercial development would face established generic competition, limited differentiation, and safety restrictions in obstetric use.
Clinical-trial outlook
| Development area |
Current assessment |
Commercial relevance |
| New asthma indication |
No material late-stage program identified |
Low |
| New inhaled terbutaline product |
Limited evidence of active branded development |
Low to moderate |
| Preterm labor |
Restricted by FDA safety actions |
Low and legally constrained |
| Neonatal respiratory use |
Specialized and institution-dependent |
Low |
| Combination product |
Potential differentiation, but no established Brethine program |
Moderate in theory |
| Generic lifecycle management |
Possible through device or formulation changes |
Limited |
For investors and licensing teams, the relevant opportunity is not conventional clinical-trial upside. It is potential lifecycle management through a differentiated delivery system, combination therapy, hospital formulation, or non-U.S. market strategy.
When does Brethine lose exclusivity?
Brethine's original regulatory and commercial exclusivity has expired. Terbutaline is an old small-molecule medicine, and the core composition-of-matter protection is no longer active in the United States.
No meaningful patent-based exclusivity is expected to protect the historical Brethine brand. Generic manufacturers can compete through abbreviated new drug applications where their products meet FDA requirements for identity, strength, quality, and bioequivalence.
Exclusivity assessment
| Protection category |
Status |
| Original compound patent |
Expired |
| Original branded-product exclusivity |
Expired |
| U.S. new chemical entity exclusivity |
Expired |
| Core terbutaline composition protection |
Expired |
| Generic approval pathway |
Available |
| Current Brethine patent moat |
No material U.S. moat identified |
| Pediatric exclusivity |
Not a current commercial protection for the legacy product |
| Orphan-drug exclusivity |
Not applicable to the core product |
The commercial barrier is therefore regulatory compliance and manufacturing economics, not patent exclusivity.
What patents protect Brethine and terbutaline?
No active U.S. patent estate is generally associated with the historical Brethine product's core active ingredient. Any remaining rights would more likely relate to a specific formulation, manufacturing process, dosage regimen, device, or combination product rather than terbutaline itself.
Formulation and method-of-use patents
Potentially relevant patent categories include:
- Modified-release oral terbutaline formulations.
- Inhaled or aerosolized terbutaline delivery systems.
- Fixed-dose combinations with corticosteroids or other bronchodilators.
- Injectable presentations with improved stability or administration characteristics.
- Specific treatment regimens for respiratory disease.
- Manufacturing processes for terbutaline sulfate or finished dosage forms.
These categories should not be treated as Brethine protections unless a patent is directly linked to the relevant product, assignee, formulation, and jurisdiction. A third-party patent covering a delivery technology could affect a future terbutaline product without protecting the historical Brethine brand.
What is the Orange Book status of Brethine?
Brethine is not a major current Orange Book reference product driving generic litigation. The product's historical regulatory status does not create current market exclusivity.
The Orange Book is relevant to listed prescription products approved under the Federal Food, Drug, and Cosmetic Act. For a legacy product such as Brethine, the commercial analysis depends on whether an active reference listing remains and whether generic approvals continue to rely on that reference product. Generic terbutaline availability indicates that the key regulatory barriers have already been overcome.
No active Orange Book patent listing is expected to create a material barrier to ordinary generic terbutaline entry. Any future patent dispute would more likely involve a newly developed formulation, device, or combination product.
Which companies are challenging Brethine exclusivity?
Generic competition has already displaced most branded Brethine demand. The relevant competitors are manufacturers of terbutaline sulfate tablets and injection, together with suppliers of alternative short-acting bronchodilators.
Potential competitive groups include:
- Generic terbutaline manufacturers
- Generic albuterol manufacturers
- Levalbuterol suppliers
- Hospital injectable-product manufacturers
- Manufacturers of inhaled corticosteroid and bronchodilator combinations
The market does not resemble a current Paragraph IV campaign against a protected branded product. Any Paragraph IV litigation associated with historical terbutaline patents would not be expected to determine the present commercial position of Brethine.
Have there been Paragraph IV challenges or Brethine patent lawsuits?
There is no current high-value Paragraph IV litigation landscape centered on Brethine comparable to litigation involving recently launched specialty medicines. The core terbutaline product is mature and genericized.
A Paragraph IV certification could arise if a manufacturer sought approval for a product referencing a listed drug with an unexpired patent. That mechanism is not expected to create a significant current barrier for conventional terbutaline tablets or injection because the historical compound and product protections have expired.
Litigation risk
| Risk category |
Assessment |
| Core compound patent litigation |
Minimal |
| Historical Brethine trademark dispute |
Limited commercial significance |
| Formulation patent litigation |
Possible for a new differentiated product |
| Device patent litigation |
Possible for an inhaled or delivery-system product |
| Manufacturing-process litigation |
Possible but product-specific |
| Obstetric-use liability |
More relevant than patent litigation |
| Generic entry litigation |
Low for conventional products |
The primary legal risk is product liability and regulatory compliance, particularly for off-label obstetric use, rather than enforcement of legacy Brethine patents.
How strong is the Brethine patent estate?
The historical Brethine patent estate is weak from a current commercial perspective. The product has no apparent protection around the basic molecule, and ordinary generic products can compete on price.
A future terbutaline product could create a stronger estate if it combined:
- A proprietary inhalation device
- A differentiated particle-size distribution
- Sustained or controlled release
- A novel fixed-dose combination
- A clinically validated dosing advantage
- A manufacturing process that is difficult to replicate
A formulation patent without clinical differentiation would face validity, obviousness, written-description, and enablement challenges. A method-of-use patent would also need a defensible patient population, dosing regimen, or clinical outcome.
What is the current market for Brethine?
Brethine itself has limited standalone market visibility because the historical brand has been replaced by generic terbutaline. Public company filings generally do not report Brethine revenue as a distinct material product line.
Market drivers
Demand for terbutaline is supported by:
- Continued use of injectable bronchodilators in hospitals
- Generic availability and low acquisition cost
- Use in selected severe bronchospasm cases
- Pediatric and specialist applications
- Availability of oral tablets where inhaled therapy is unsuitable
Demand is constrained by:
- Albuterol's dominant physician familiarity
- Greater use of inhaled therapy in asthma guidelines
- Cardiovascular and systemic adverse effects
- Limited role in chronic maintenance treatment
- FDA restrictions on obstetric use
- Low pricing and limited brand differentiation
Revenue exposure
| Revenue category |
Exposure to Brethine |
| Historical branded Brethine revenue |
Low or immaterial |
| Generic oral terbutaline |
Low-value, mature revenue |
| Generic injectable terbutaline |
More defensible hospital demand |
| U.S. asthma market |
Small share |
| Global beta-2 agonist market |
Very small share |
| Potential reformulated product |
Unproven and dependent on clinical differentiation |
A standalone Brethine revenue forecast would be unreliable because the brand is not a separately disclosed growth product. A realistic projection should address the broader terbutaline market instead.
What is the 2025–2030 market projection for Brethine?
The base case is stable to declining revenue for conventional terbutaline products. Unit demand may remain resilient in hospitals and selected specialist settings, but price erosion and substitution by inhaled albuterol are likely to limit revenue growth.
| Scenario |
2025–2030 outlook |
Main assumptions |
| Base case |
Low-single-digit annual revenue decline |
Mature generic pricing, stable hospital use, continued substitution |
| Upside case |
Flat to low-single-digit growth |
Injectable supply disruptions, new formulation, institutional demand |
| Downside case |
Mid-single-digit annual decline |
Further albuterol substitution, supplier exits, tighter obstetric enforcement |
| Branded redevelopment case |
Potentially higher growth from a low base |
Requires new device, combination, or controlled-release product and clinical support |
The most attractive commercial segment is injectable terbutaline, where hospital purchasing and supply reliability can be more important than brand recognition. Oral terbutaline has weaker growth prospects because systemic adverse effects and the availability of inhaled alternatives reduce its role.
How does Brethine compare with albuterol and levalbuterol?
| Factor |
Terbutaline/Brethine |
Albuterol |
Levalbuterol |
| Primary route |
Oral and injectable |
Inhaled, nebulized, oral options |
Inhaled and nebulized |
| Outpatient asthma position |
Limited |
Dominant short-acting rescue option |
Niche alternative |
| Systemic exposure |
Higher with oral therapy |
Lower with inhaled delivery |
Lower with inhaled delivery |
| Generic competition |
Extensive |
Extensive |
Extensive |
| Differentiation potential |
Delivery and formulation |
Device and combination products |
Tolerability and device |
| Patent strength |
Weak for legacy product |
Product-specific, mostly mature |
Product-specific, mostly mature |
| Growth outlook |
Flat to declining |
Broad but mature |
Niche |
Terbutaline's competitive disadvantage is route of administration. Oral dosing produces more systemic exposure than inhaled rescue therapy, while injectable use is reserved for selected acute or institutional situations.
What generic launch risks exist for Brethine?
Conventional generic entry risk is already realized. The main risks are commercial rather than prospective:
- Additional generic suppliers can intensify price competition.
- A manufacturer exit can create temporary shortages but may not support durable pricing.
- Hospital contracts can shift rapidly based on supply and cost.
- A new inhaled or extended-release product could redirect demand from oral terbutaline.
- Regulatory enforcement could reduce off-label obstetric utilization.
- Manufacturing changes may trigger supply interruptions if few suppliers remain.
A new entrant would face low patent risk but meaningful commercialization risk. FDA approval alone would not guarantee attractive returns in a low-priced generic category.
Is there licensing or partnering activity for Brethine?
No major current licensing transaction is associated with Brethine as a standalone brand. Any viable partnering opportunity would likely involve:
- A new inhalation platform
- A combination respiratory product
- A hospital injectable portfolio
- A regional commercialization agreement
- A reformulated product with new clinical data
Licensing the legacy Brethine brand without differentiated intellectual property would offer limited strategic value. The asset could have more relevance in markets where terbutaline remains widely used and local manufacturing or distribution is constrained.
What is the geographic market outlook for terbutaline?
The U.S. market is mature and genericized. International demand varies according to asthma treatment guidelines, access to inhalers, hospital procurement practices, and local regulatory treatment of obstetric use.
| Region |
Commercial outlook |
| United States |
Mature, low growth; injectable niche remains relevant |
| Europe |
Limited growth; inhaled alternatives and guideline pressure dominate |
| Japan |
Product-specific and regulated market; limited legacy-brand opportunity |
| Latin America |
Generic demand may remain steady, especially where oral products are used |
| Asia-Pacific |
Larger unit opportunity, but pricing and local competition are significant |
| Middle East and Africa |
Potential access-driven demand; distribution and registration are key barriers |
Geographic opportunity is stronger where terbutaline remains accessible through low-cost oral or injectable channels and where inhaler access is uneven. Patent barriers are generally limited; registration, quality systems, procurement access, and local manufacturing capacity are more important.
Key Takeaways
- Brethine is the historical brand for terbutaline sulfate and has limited current standalone commercial importance.
- Terbutaline remains available mainly as a generic oral tablet and injectable product.
- No material late-stage clinical-trial program is associated with a new Brethine product.
- The original compound and brand exclusivity have expired.
- Current Orange Book and Paragraph IV activity is not expected to create a meaningful barrier for conventional terbutaline products.
- Injectable terbutaline has the strongest remaining commercial niche, particularly in hospitals.
- Oral terbutaline faces continued substitution by inhaled albuterol and other modern respiratory therapies.
- The 2025–2030 base case is stable to declining revenue for conventional terbutaline.
- Commercial upside would require a differentiated formulation, delivery system, combination product, or regional market strategy.
- Manufacturing, supply reliability, regulatory compliance, and hospital contracting are more important than legacy patent rights.
Frequently Asked Questions About Brethine
Is Brethine still available in the United States?
The Brethine brand has limited current market presence. Terbutaline sulfate remains available through generic prescription products, including tablets and injectable formulations.
Is Brethine the same as albuterol?
No. Both are beta-2 adrenergic agonists, but Brethine contains terbutaline and albuterol contains salbutamol. Albuterol is more widely used as an inhaled rescue bronchodilator.
Can terbutaline still be used for preterm labor?
FDA restrictions limit terbutaline use for preterm labor. Prolonged treatment and outpatient or home use are not appropriate under the FDA safety communication because of serious maternal cardiovascular risks.[1]
Does terbutaline have biosimilar competition?
No. Terbutaline is a small-molecule drug, so competing products are generics approved through abbreviated new drug applications, not biosimilars.
Would a new inhaled terbutaline product receive patent protection?
A new inhaled product could receive patents for a device, formulation, manufacturing process, or therapeutic use if it satisfies patentability requirements. Such rights would protect the new product, not the expired terbutaline molecule itself.
References
-
U.S. Food and Drug Administration. (2011, February 17). FDA drug safety communication: New warnings against use of terbutaline to treat preterm labor. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-warnings-against-use-terbutaline-treat-preterm-labor
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
-
Global Initiative for Asthma. (2024). Global strategy for asthma management and prevention. https://ginasthma.org/
